Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the companyâs transformative, high precision ophthalmic delivery platform. Eyenoviaâs pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases. Source
No articles found.
HealthEquity provides a solution to an issue of growing importance to American fam...
HealthEquity provides a solution to an issue of...
Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...
Neoleukin is a biopharmaceutical company creati...
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully...
Titan is a specialty pharmaceuticals company that develops therapeutics for select...
Titan is a specialty pharmaceuticals company th...
NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisens...
NeuBase Therapeutics, Inc. is developing its mo...
Join the National Investor Network and get the latest information with your interests in mind.